Advertisement

Antipurines

  • D. M. Tidd
Part of the Handbook of Experimental Pharmacology book series (HEP, volume 72)

Abstract

The antipurines comprise a group of structural analogues of naturally occurring purine bases and nucleosides which exhibit cell growth inhibitory properties. A large number of purine and purine nucleoside analogues have been investigated for antitumour activity, but of these only a few have proved of sufficient interest as potentially useful clinical anticancer agents to warrant detailed studies of resistance. Such compounds include: 8-azaguanine (AzaG), 6-mercaptopurine (MP), 6-thioguanine (TG), 6-methylthioinosine (MMPR) and 9-β-d-arabinofuranosyladenine (AraA). The chemical structures of these drugs are presented in Fig. 1. The 6-thiopurines, MP and TG, are the only antipurines to achieve widespread routine clinical use in cancer chemotherapy, and consequently they have received considerable attention in the laboratory.

Keywords

Adenosine Deaminase Purine Nucleoside Ehrlich Ascites Carcinoma Purine Nucleotide Purine Nucleoside Phosphorylase 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Adamson RH, Zaharevitz DW, Johns DG (1977) Enhancement of the antileukemic activity of 9-β-D-xylofuranosyladenine (xylo-A) and other adenosine analogs by 2’-deoxycoformycin (2’-DCF) and by eryrhro-9-(2-hydroxy-3-nonyl) adenine (EHNA). Proc Am Assoc Cancer Res 18:147Google Scholar
  2. Agarwal KC, Chu S-H, Ross AF, Gorske AF, Parks RE Jr (1971) Antitumor action of 6-selenoguanine and 6-selenoguanosine. Pharmacologist 13:210Google Scholar
  3. Albertini RJ, De Mars R (1970) Diploid azaguanine-resistant mutants of cultured human fibroblasts. Science 169:482–485Google Scholar
  4. Anderson D (1975) Attempts to produce systems for isolating spontaenous and induced variants in various lymphoma cells using a variety of selective agents. Mutat Res. 33:407–416PubMedGoogle Scholar
  5. Anderson EP, Heppel LA (1960) Purification and properties of a leukemic cell phosphodiesterase. Biochim Biophys Acta 43:79–89PubMedGoogle Scholar
  6. Avramis VI, Plunkett W (1982) Metabolism and therapeutic efficacy of 9-β-D-arabino-furanosyl-2-fluoroadenine against murine leukemia P388. Cancer Res 42:2587–2591PubMedGoogle Scholar
  7. Baer H-P, Drummond GI, Duncan EL (1966) Formation and deamination of adenosine by cardiac muscle enzymes. Mol Pharmacol 2:67–76PubMedGoogle Scholar
  8. Bakay B, Nyhan WL (1972) Electrophoretic properties of hypoxanthine-guanine phospho-ribosyltransferase in erythrocytes of subjects with Lesch-Nyhan syndrome. Biochem Genet 6:139–146PubMedGoogle Scholar
  9. Baudet AL, Roufa DA, Caskey CT (1973) Mutations affecting the structure of hypoxanthine-guanine phosphoribosyl transferase in cultured Chinese hamster cells. Proc Natl Acad Sci USA 70:320–324Google Scholar
  10. Benke PJ, Herrick N, Hebert A (1973) Hypoxanthine-guanine phosphoribosyltransferase variant associated with accelerated purine synthesis. J Clin Invest 52:2234–2240PubMedGoogle Scholar
  11. Bennett LL Jr, Brockman RW, Schnebli HP, Chumley S, Dixon GJ, Schabel FM Jr, Dulmadge EA, Skipper HE, Montgomery J A, Thomas HJ (1965) Activity and mechanism of action of 6-methylthiopurine ribonucleoside in cancer cells resistant to 6-mercaptopurine. Nature 205:1276–127Google Scholar
  12. Bennett LL Jr, Schnebli HP, Vail MH, Allan PW, Montgomery JA (1966 a) Purine ribonucleoside kinase activity and resistance to some analogs of adenosine. Mol Pharmacol 2:432–443PubMedGoogle Scholar
  13. Bennett LL Jr, Vail MH, Chumley S, Montgomery JA (1966 b) Activity of adenosine analogs against a cell culture line resistant to 2-fluoroadenine. Biochem Pharmacol 15:1719–1728Google Scholar
  14. Bennett LL Jr, Allan PW, Hill DL (1968) Metabolic studies with carbocyclic analogs of purine nucleosides. Mol Pharmacol 4:208–217PubMedGoogle Scholar
  15. Bennett LL Jr, Allen PW, Smithers D, Vail MH (1969) Resistance to 4-aminopyrazolo (3,4-d) pyrimidine. Biochem Pharmacol 18:725–740PubMedGoogle Scholar
  16. Bennett LL Jr, Vail MH, Allan PW, Laster WR Jr (1973) Studies with 8-azainosine, a cytotoxic nucleoside with antitumor activity. Cancer Res 33:465–471PubMedGoogle Scholar
  17. Bennett LL Jr, Montgomery J A, Brockman RW Shealy YF (1978) Design of analogs of purine nucleosides with specifically altered activities as substrates for nucleoside metabolizing enzymes. In: Weber G (ed) Advances in enzyme regulation, vol 16. Pergamon, Oxford p 255Google Scholar
  18. Bennett LL Jr, Rose LM, Allan PW, Smithers D, Adamson DJ, Elliot RD, Montgomery J A (1979) Metabolism and metabolic effects of 8-aza-6-thioinosine and its rearrangement product, N-β-D-ribofuranosyl-[1, 2, 3] thiadiazolo [5, 4,-d)-pyrimidin-7-amine. Mol Pharmacol 16:981–996PubMedGoogle Scholar
  19. Berman J J, Tong C, Williams GM (1980) Differences between rat liver epithelial cells and fibroblast cells in sensitivity to 8-azaguanine. In Vitro 16:661–668Google Scholar
  20. Bieber AL, Sartorelli AC (1964) The metabolism of thioguanine in purine analogue-resistant cells. Cancer Res 24:1210–1215PubMedGoogle Scholar
  21. Bloch A (ed) (1975) Chemistry, biology and clinical uses of nucleoside analogs. Ann NY Acad Sci 255Google Scholar
  22. Bodey GP, Brodovsky HS, Issassi A A, Samuels ML, Freireich EJ (1968) Studies of combination 6-mercaptopurine (NSC-755) and 6-methylmercaptopurine riboside (NSC-40774) in patients with acute leukemia and metastatic cancer. Cancer Chemother Rep. 52:315–320PubMedGoogle Scholar
  23. Brennand J, Chinault AC, Konecki DS, Melton DW, Caskey CT (1982) Cloned cDNA sequences of the hypoxanthine/guanine phosphoribosyltransferase gene from a mouse neuroblastoma cell line found to have amplified genomic sequences. Proc Natl Acad Sci USA 79:1950–1954PubMedGoogle Scholar
  24. Brockman RW (1960) A mechanism of resistance to 6-mercaptopurine: metabolism of hypoxanthine and 6-mercaptopurine by sensitive and resistant neoplasms. Cancer Res 20:643–653PubMedGoogle Scholar
  25. Brockman RW (1963) Mechanisms of resistance to anticancer agents. In: Haddow A, Weinhouse S (eds) Advances in cancer research, vol. 7 Academic, New York p 129Google Scholar
  26. Brockman RW (1974) Mechanism of resistance. In: Sartorelli AC, Johns DG (eds) Antineoplastic and immunosuppressive agents. Springer, Berlin Heidelberg New York (Handbook of experimental pharmacology, vol 38/1, p 352)Google Scholar
  27. Brockman RW, Chumley S (1965) Inhibition of formylglycinamide ribonucleotide synthesis in neoplastic cells by purines and analogs. Biochim Biophys Acta 95:365–379PubMedGoogle Scholar
  28. Brockman RW, Sparks MC, Simpson MS (1957) A comparison of the metabolism of purines and purine analogs by susceptible and drug-resistant bacterial and neoplastic cells. Biochim Biophys Acta 26:671–672PubMedGoogle Scholar
  29. Brockman RW, Sparks MC, Hutchison DJ, Skipper HE (1959 a) A mechanism of resistance to 8-azaguanine I. Microbiological studies on the metabolism of purines and 8-azapurines. Cancer Res 19:177–188PubMedGoogle Scholar
  30. Brockman RW, Bennett LL Jr, Simpson MS, Wilson AR, Thomson JR, Skipper HE (1959 b) A mechanism of resistance to 8-azaguanine. II. Studies with experimental neoplasms. Cancer Res. 19:856–869PubMedGoogle Scholar
  31. Brockman RW, Kelley GG, Stutts P, Copeland V (1961) Biochemical aspects of resistance to 6-mercaptopurine in human epidermoid carcinoma cells in culture. Nature 191:469–471Google Scholar
  32. Brockman RW, Schabel FM Jr, Montgomery J A (1977) Biologic activity of 9-β-D-ara- binofuranosyl-2-fluoroadenine, a metabolically stable analog of 9-β-D-arabinofuranosyladenine. Biochem Pharmacol 26:2193–2196PubMedGoogle Scholar
  33. Brockman RW, Cheng Y-C, Schabel FM Jr, Montgomery JA (1979) Metabolism and chemotherapeutic effects of 9-β-D-arabinofuranosyl-2-fluoroadenine (F-AraA) and evidence for its activation by deoxycytidine kinase. Proc Am Assoc Cancer Res 20:37Google Scholar
  34. Brockman RW, Cheng Y-C, Schabel FM Jr, Montgomery J A (1980) Metabolism and chemotherapeutic activity of 9-β-D-arabinofuranosyl-2-fluoradenine against murine leukemia LI210 and evidence for its phosphorylation by deoxycytidine kinase. Cancer Res 40:3610–3615PubMedGoogle Scholar
  35. Brox LW, Birkett L, Belch A (1981) Clinical pharmacology of oral thioguanine in acute myelogenous leukemia. Cancer Chemother Pharmacol 6:35–38PubMedGoogle Scholar
  36. Burchenal JH, Dollinger MR (1967) Cytosine arabinoside (NSC-63878) in combination with 6-mercaptopurine (NSC-755), methotrexate (NSC-740), or 5-fluorouracil (NSC-19893) in L1210 mouse leukaemia. Cancer Chemother Rep 51:435–438Google Scholar
  37. Caldwell IC, Henderson JF, Paterson ARP (1967) Resistance to purine ribonucleoside analogues in an ascites tumor. Can J Biochem 45:735–744PubMedGoogle Scholar
  38. Carson DA, Kaye J, Seegmiller JE (1980) Metabolism and toxicity of 9-β-D-arabinofuranosyladenine in human malignant T cells and B cells in tissue culture. In: Rapado A, Watts RWE, De Bruyn CHMM (eds) Purine metabolism in man. III. Biochemical, immunological and cancer research. Plenum, New York p 299Google Scholar
  39. Caskey CT, Kruh GD (1979) The HPRT locus. Cell 16:1–9Google Scholar
  40. Cass CE (1979) 9-β-D-Arabinofuranosyladenine (AraA). In: Hahn FE (ed) Mechanism of action of antieukaryotic and antiviral compounds. Springer, Berlin Heidelberg New York (Antibiotics, vol 5–2, p 85)Google Scholar
  41. Cass CE, Au-Yeung TH (1976) Enhancement of 9-β-D-arabinofuranosyl-adenine cytotoxicity to mouse leukemia L1210 in vitro by 2’-deoxycoformycin. Cancer Res. 36:1486–1491PubMedGoogle Scholar
  42. Cass CE, Tan TH, Seiner M (1979) Antiproliferative effects of 9-β-D-arabinofuranosyladenine 5′-monophosphate and related compounds in combination with adenosine inhibitors against mouse leukemia L1210/C2 cells in culture. Cancer Res. 39:1563–1569PubMedGoogle Scholar
  43. Changas GS, Milman G (1977) Hypoxanthine phosphoribosyltransferase: two dimensional gels from normal and Lesch-Nyhan hemolyzates. Science 196:1119–1120Google Scholar
  44. Chasin LA, Urlaub G (1976) Mutant alleles for hypoxanthine phosphoribosyltransferase: codominant expression, complementation, and segregation in hybrid Chinese hamster cells. Somatic Cell Genet 2:453–467PubMedGoogle Scholar
  45. Coddington A (1965) Some substrates and inhibitors of adenosine deaminase. Biochim Biophys Acta 99:442–451PubMedGoogle Scholar
  46. Coffey J J, White CA, Lesk AB, Rogers WI, Serpick AA (1972) Effect of allopurinol on the pharmacokinetics of 6-mercaptopurine (NSC 755) in cancer patients. Cancer Res 32:1283–1289PubMedGoogle Scholar
  47. Cohen SS, Plunkett W (1975) The utilization of nucleotides by animal cells. Ann NY Acad Sci 255:269PubMedGoogle Scholar
  48. Crabtree GW (1978) Mechanisms of action of pyrimidine and purine analogs. In: Brodsky I, Kahn SB, Conroy JF (eds) Cancer chemotherapy III. 46 th Hahnemann symposium. Grune & Stratton, New York, p 35Google Scholar
  49. Crabtree GW, Nelson JA, Parks RE Jr (1977) Failure of 6-thio GMP to inhibit guanylate kinase in intact cells. Biochem Pharmacol 26:1577–1584PubMedGoogle Scholar
  50. Davidson JD (1960) Studies on the mechanism of action of 6-mercaptopurine in sensitive and resistant LI210 leukemia in vitro. Cancer Res 20:225–232PubMedGoogle Scholar
  51. Davidson JD, Winter TS (1964) Purine nucleoside pyrophosphorylases in 6-mercaptopurine-sensitive and -resistant human leukemias. Cancer Res 24:261–267PubMedGoogle Scholar
  52. Davidson JD, Bradley TR, Roosa RA, Law LW (1962) Purine nucleotide pyrophosphorylases in 8-azaguanine-sensitive and -resistant leukemias. J Natl Cancer Inst 29:789–800PubMedGoogle Scholar
  53. Divekar AY, Fleysher MH, Slocum HK, Kenny LN, Hakala MT (1972) Changes in sarcoma 180 cells associated with drug-induced resistance to adenosine analogs. Cancer Res 32:2530–2537PubMedGoogle Scholar
  54. Dooley T, Maddocks JL (1982) Assay of an active metabolite of 6-thioguanine, 6-thioguanosine 5′-monophosphate, in human red blood cells. J Chromatogr 229:121–127PubMedGoogle Scholar
  55. Elion GB (1967) Biochemistry and pharmacology of purine analogues. Fed Proc 26:898–908Google Scholar
  56. Elion GB (1975) Interaction of anticancer drugs with enzymes. In: Pharmacological basis of cancer chemotherapy. Williams & Wilkins, Baltimore, p 547Google Scholar
  57. Elion GB, Hitchings GH (1975) Azathioprine: In: Sartorelli AC, Johns DG (eds) Antineoplastic and immunosuppressive agents. Springer, Berlin Heidelberg New York (Handbook of experimental pharmacology, vol 38/2, p 404)Google Scholar
  58. Elion GB, Callahan S, Bieber S, Hitchings GH, Rundles RW (1961) A summary of investigations with 6-[(l-methyl-4-nitro-5-imidazolyl) thio] purine (B.W. 57–322). Cancer Chemother Rep 14:93–98Google Scholar
  59. Elion GB, Callahan S, Nathan H, Bieber S, Rundles RW, Hitchings GH (1963) Potentiation by inhibition of drug degradation: 6-substituted purines and xanthine oxidase. Biochem Pharmacol 12:85–93Google Scholar
  60. Ellis DB, LePage GA (1963) Biochemical studies of resistance to 6-thioguanine. Cancer Res 23:436–443Google Scholar
  61. Epps D, Chang I-M, Sherwood E, Kimball AP (1975) Feedback inhibition by 6-methylthioinosine 3′,5′-cyclic monophosphate in tumor cells resistant to the nucleoside. Proc Soc Exp Biol Med 150:578–580PubMedGoogle Scholar
  62. Epstein J, Leyva A, Kelley WN, Littlefield JW (1977) Mutagen-induced diploid human lymphoblast variants containing altered hypoxanthine guanine phosphoribosyl transferase. Somatic Cell Genet 3:135–148PubMedGoogle Scholar
  63. Fenwick RG Jr, Caskey CT (1975) Mutant Chinese hamster cells with a thermosensitive hypoxanthine-guanine phosphoribosyltransferase. Cell 5:115–122PubMedGoogle Scholar
  64. Fen wick RG Jr, Wasmuth J J, Caskey CT (1977 a) Mutations affecting the antigenic properties of hypoxanthine-guanine phosphoribosyltransferase in cultured Chinese hamster cells. Somatic Cell Genet 3:207–216PubMedGoogle Scholar
  65. Fenwick RG Jr, Sawyer TH, Kruh GD, Astrin KH, Caskey CT (1977 b) Forward and reverse mutations affecting the kinetics and apparent molecular weight of mammalian HGPRT. Cell 12:383–391Google Scholar
  66. Finnish Leukaemia Group (1979) The effect of thioguanine on a combination of daunorubicine, cytarabine and prednisone in the treatment of acute leukaemia in adults. Scand J Haematol 23:124–128Google Scholar
  67. Fox M, Hodgkiss RJ (1981) Mechanism of cytotoxic action of azaguanine and thioguanine in wild-type V79 cell lines and their relative efficiency in selection of structural gene mutants. Mutat Res 80:165–185PubMedGoogle Scholar
  68. Fox IH, Kelley WN (1971) Phosphoribosylpyrophosphate in man: biochemical significance. Ann Intern Med 74:424–433PubMedGoogle Scholar
  69. Fox M, Radacic M (1978) Adaptational origin of some purine analogue resistant pheno-types in cultured mammalian cells. Mutat Res 49–275–296PubMedGoogle Scholar
  70. Fox M, Radacic M (1982) Variations in chromosome numbers and their possible relationship to the development of 8-azaguanine resistance in V79 Chinese hamster cells. Cell Biol Int Rep 6:39–48PubMedGoogle Scholar
  71. Fox M, Boyle JM, Fox BW (1976) Biological and biochemical characterisation of purine analogue resistant clones of V79 Chinese hamster cells. Mutat Res 35:289–310PubMedGoogle Scholar
  72. Friedrich U, Coffino P (1977) Hypoxanthine-guanine phosphoribosyl transferase with altered substrate affinity in mutant mouse lymphoma cells. Biochim Biophys Acta 483:70–78PubMedGoogle Scholar
  73. Gee TS, Yu KP, Clarkson BD (1969) Treatment of adult acute leukemia with arabinosyl-cytosine and thioguanine. Cancer 23:1019–1032PubMedGoogle Scholar
  74. Gellhorn A (1953) Laboratory and clinical studies on 8-azaguanosine. Cancer 6:1030–1033PubMedGoogle Scholar
  75. Gillin FD, Roufa DJ, Beaudet AL, Caskey CT (1972) 8-Azaguanine resistance in mammalian cells I. Hypoxanthine-guanine phosphoribosyltransferase. Genetics 72:239–252PubMedGoogle Scholar
  76. Grindey GB (1979) Clinical pharmacology of the 6-thiopurines. Cancer Treat Rev [Suppl] 6:19–25Google Scholar
  77. Grunberger D, Grunberger G (1979) 8-Azaguanine. In: Hahn FE (ed) Mechanism of action of antieukaryotic and antiviral compounds. Springer, Berlin Heidelberg New York (Antibiotics, vol 5/2, p 110)Google Scholar
  78. Gupta RS, Siminovitch L (1978) Genetic and biochemical studies with the adenosine analogs toyocamycin and tubercidin: mutation at the adenosine kinase locus in Chinese hamster cells. Somatic Cell Genet 4:715–735PubMedGoogle Scholar
  79. Hakala MT (1970) Properties of sarcoma 180 (S-180) cells resistant to kinetin riboside (KR). Fed Proc. 29:884Google Scholar
  80. Hakala MT (1973) Enzyme changes in resistant tissues. In: Mihich E (ed) Drug resistance and selectivity. Biochemical and cellular basis. Academic, New York, p 263Google Scholar
  81. Hakala MT (1974) Transport of antineoplastic agents. In: Sartorelli AC, Johns DG (eds) Antineoplastic and immunosuppressive agents. Springer, Berlin Heidelberg New York (Handbook of experimental pharmacology, Vol 38/1, p 240)Google Scholar
  82. Harris BA, Plunkett W (1981) Biochemical basis for the cytotoxicity of 9-β-D-xylo-furanosyladenine in Chinese hamster ovary cells. Cancer Res 41:1039–1044PubMedGoogle Scholar
  83. Harris BA, Saunders PP, Plunkett W (1981) Metabolism of 9-β-D-xylofuranosyladenine by the Chinese hamster ovary cell. Mol Pharmacol 20:200–205PubMedGoogle Scholar
  84. Harris JF, Whitmore GF (1974) Chinese hamster cells exhibiting a temperature-dependent alteration in purine transport: J Cell Physiol 83:43–52PubMedGoogle Scholar
  85. Harris M (1971) Mutation rates in cells at different ploidy levels. J Cell Physiol 78:177–184PubMedGoogle Scholar
  86. Henderson JF (1974) Biochemical aspects of selective toxicity. In: Sartorelli AC, Johns DG (eds) Antineoplastic and immunosuppressive agents. Springer, Berlin Heidelberg New York (Handbook of experimental pharmacology, vol 38/1, p 341)Google Scholar
  87. Henderson JF (1977) Analogs of purines and purine nucleosides: biological and biochemical effects. In: Quagliariello E, Palmieri F, Singer TP (eds) Horizons in biochemistry and biophysics, vol 4. Addison-Wesley, Reading, p 130Google Scholar
  88. Henderson JF, Broekman RW (1975) Biochemical mechanisms of drug resistance in cancer chemotherapy. In: Pharmacological basis of cancer chemotherapy. Williams & Wilkins, Baltimore, p 629Google Scholar
  89. Henderson JF, Khoo MKY (1965) Synthesis of 5-phosphoribosyl 1-pyrophosphate from glucose in Ehrlich ascites tumor cells in vitro. J Biol Chem 240:2349–2357PubMedGoogle Scholar
  90. Henderson JF, Caldwell IC, Paterson ARP (1967) Decreased feedback inhibition in a 6-(methylmercapto)purine ribonucleoside-resistant tumor. Cancer Res 27:1773–1778PubMedGoogle Scholar
  91. Henderson JF, Brox LW, Fraser JH, Lomax CA, McCoy EE, Snyder FF, Zombor G (1975) Models and methods for biochemical studies of resistance in man: In: Pharmacological basis of cancer chemotherapy. Williams & Wilkins, Baltimore, p 663Google Scholar
  92. Higuchi T (1974) Phosphorylation of 6-mercaptopurine in human leukemic cells. Acta Haematol Jpn 37:282–288Google Scholar
  93. Higuchi T (1975) Phosphorylation of 6-mercaptopurine in human leukemic cells and phos-phoribosylpyrophosphate. Acta Haematol Jpn 38:248–258Google Scholar
  94. Higuchi T, Nakamura T, Wakisaka G (1976) Metabolism of 6-mercaptopurine in human leukemic cells. Cancer Res 36:3779–3783PubMedGoogle Scholar
  95. Higuchi T, Nakamura T, Uchino H, Wakisaka G (1977) Comparative study of 6-mercaptopurine metabolism in human leukemic leukocytes and LI210 cells. Antimicrob Agents Chemother 12:518–522PubMedGoogle Scholar
  96. Hill DL (1970) Hypoxanthine phosphoribosyltransferase and guanine metabolism of adenocarcinoma 755 cells. Biochem Pharmacol 19:545–557PubMedGoogle Scholar
  97. Hirschberg E, Kream J, Gellhorn A (1952) Enzymatic deamination of 8-azaguanine in normal and neoplastic tissues. Cancer Res 12:524–528PubMedGoogle Scholar
  98. Hitchings GH, Elion GB (1967) Mechanisms of action of purine and pyrimidine analogs. In: Brodsky I, Kahn SB, Moyer JH (eds) Cancer chemotherapy. Grune & Stratton, New York, p 26Google Scholar
  99. Hitchings GH, Elion GB (1969) The role of antimetabolites in immunosuppression and transplantation. Acc Chem Res 2:202–209Google Scholar
  100. Ho DHW (1971) Metabolism of 6-methylthiopurine ribonucleoside 5′-phosphate. Biochem Pharmacol 20:3538–3539PubMedGoogle Scholar
  101. Ho DHW, Luce JK, Frei E (1968) Distribution of purine ribonucleoside kinase and selective toxicity of 6-methylthiopurine ribonucleoside. Biochem Pharmacol 17:1025–1035PubMedGoogle Scholar
  102. Hodgkiss RJ, Fox M (1980) Characteristics of revertants induced by EMS and UV light from a 6-thioguanine resistant HGPRT deficient V79 Chinese hamster cell line. Carcinogenesis 1:189–198Google Scholar
  103. Hodgkiss RJ, Brennand J, Fox M (1980) Reversion of 6-thioguanine resistant Chinese hamster cell lines: agent specificity and evidence for the repair of promutagenic lesions. Carcinogenesis 1:175–187Google Scholar
  104. Hughes RG Jr, Kimball AP (1972) Metabolic effects of cyclic 9-β-Arabinofuranosylade-nine 3′,5′-monophosphate in L1210 cells. Cancer Res 32:1791–1794PubMedGoogle Scholar
  105. Hutchison DJ (1963) Cross-resistance and collateral sensitivity studies in cancer chemotherapy. In: Haddow A, Weinhouse S (eds) Advances in cancer research, vol 7. Academic, New York, p 235Google Scholar
  106. Jackson RC, Ross DA, Harkrader RJ, Epstein J (1980) Biochemical approaches to enhancement of antitumor drug selectivity: selective protection of cells from 6-thioguanine and 6-mercaptopurine by adenosine. Cancer Treat Rep 64:1347–1353PubMedGoogle Scholar
  107. Johns DG; Adamson RH (1976) Enhancement of the biological activity of cordycepin (3′-deoxyadenosine) by the adenosine deaminase inhibitor 2’-deoxycoformycin. Biochem Pharmacol 25:1441–1444PubMedGoogle Scholar
  108. Johnson GG, Eisenberg LR, Migeon BR (1979) Human and mouse hypoxanthine-guanine phosphoribosyltransferase: dimers and tetramers. Science 203:174–176PubMedGoogle Scholar
  109. Kadouri A, Kunce JJ, Lark KG (1978) Evidence for dominant mutations reducing HGPRT activity. Nature 274:256–259PubMedGoogle Scholar
  110. Kessel D, Hall TC (1969) Retention of 6-mercaptopurine derivatives by intact cells as an index of drug response in human and murine leukemias. Cancer Res 29:2116–2119PubMedGoogle Scholar
  111. Kim K, Blechman WJ, Riddle YGH, Pardee AB (1981) Basis of observed resistance of LI210 leukemia in mice to methotrexate, 6-thioguanine, 6-methylmercaptopurine riboside, 6-mereaptopurine, 5-fluorouracil, and l-β-D-arabinofuranosylcytosine administered in different combinations. Cancer Res 41:4529–4534PubMedGoogle Scholar
  112. Kimball AP, LePage GA, Bowman B (1964) The metabolism of 9-arabinosyl-6-mercapto-purine in normal and neoplastic tissues. Can J Biochem 42:1753–1768PubMedGoogle Scholar
  113. Kondo T, Maruyama T (1955) The influence of 8-azaguanine on tumors and its enhancement. Gan 42:503–506Google Scholar
  114. Kong CM, Parks RE Jr (1974) Human erythrocytic hypoxanthine-guanine phospho-ribosyltransferase: effect of pH on the enzymatic reaction. Mol Pharmacol 10:648–656Google Scholar
  115. Koontz JW, Wicks WD (1977) Comparison of the effects of 6-thio- and 6-methylthiopurine ribonucleoside cyclic monophosphates with their corresponding nucleosides on the growth of rat hepatoma cells. Cancer Res 37:651–657PubMedGoogle Scholar
  116. Koshiura R, LePage GA (1968) Some inhibitors of deamination of 9-β-D-arabinofurano-syladenine and 9-β-D-xylofuranosyladenine by blood and neoplasms of experimental animals and humans. Cancer Res 28:1014–1020Google Scholar
  117. Krenitsky TA, Papaioannou R, Elion GB (1969) Human hypoxanthine phosphoribosyl-transferase 1. Purification, properties and specificity. J Biol Chem 244:1263–1270PubMedGoogle Scholar
  118. Kruh GD, Fenwick RG Jr., Caskey CT (1981) Structural analysis of mutant and revertant forms of Chinese hamster hypoxanthine-guanine phosphoribosyltransferase. J Biol Chem 256:2878–2886PubMedGoogle Scholar
  119. Kusmierek JT, Shugar D (1979) Nucleotides, nucleoside phosphate diesters and phosphonates as antiviral and antineoplastic agents - an overview. In: Chandra P (ed) Antiviral mechanisms in the control of neoplasia. Plenum, New York (NATO) advanced study institutes, ser A, vol 20, p 481)Google Scholar
  120. Lee SH, Sartorelli AC (1981a) The effects of inhibitors of DNA biosynthesis on the cytotoxicity of 6-thioguanine. Cancer Biochem Biophys 5:189–194PubMedGoogle Scholar
  121. Lee SH, Sartorelli AC (1981 b) Conversion of 6-thioguanine to the nucleoside level by purine nucleoside phosphorylase of sarcoma 180 and sarcoma 180/TG ascites cells. Cancer Res 41:1086–1090Google Scholar
  122. Lee SH, Sartorelli AC (1981 c) Biochemical mechanism of resistance of cultured sarcoma 180 cells to 6-thioguanine. Biochem Pharmacol 30:3109–3114PubMedGoogle Scholar
  123. Lee MH, Huang Y-M, Sartorelli AC (1978) Alkaline phosphatase activities of 6-thiopurine-sensitive and -resistant sublines of sarcoma 180. Cancer Res 38:2413–2418PubMedGoogle Scholar
  124. Lee SH, Shansky CW, Sartorelli AC (1980) Evidence for the external location of alkaline phosphatase activity on the surface of sarcoma 180 cells resistant to 6-thioguanine. Biochem Pharmacol 29:1859–1861PubMedGoogle Scholar
  125. Lee SH, Thomas LK, Unger FM, Christian R, Sartorelli AC (1981) Comparative antineoplastic activity against P388 leukemia of 9-β-D-arabinofuranosyladenine (araA) and 9-β-(2-azido-2’-deoxy-D-arabinofuranosyl)adenine (arazide). Int J Cancer 27:703–708PubMedGoogle Scholar
  126. LePage GA (1968) The metabolism of a-2’-deoxythioguanosine in murine tumor cells. Can J Biochem 46:655–661PubMedGoogle Scholar
  127. LePage GA (1970) Alterations in enzyme activity in tumors and the implications for chemotherapy. In: Weber G (ed) Advances in enzyme regulation, vol. 8. Pergamon, Oxford, p 323Google Scholar
  128. LePage GA (1975 a) Introduction to resistance to cancer chemotherapy section. In: Pharmacological basis of cancer chemotherapy. Williams & Wilkins, Baltimore, p 627Google Scholar
  129. LePage GA (1975 b) Purine arabinosides, xylosides and lyxosides. In: Sartorelli AC, Johns DG (eds) Antineoplastic and immunosuppressive agents. Springer, Berlin Heidelberg New York (Handbook of experimental pharmacology, vol 38/2, p 426)Google Scholar
  130. LePage GA (1977) Purine antagonists. In: Becker FF (ed) Chemotherapy. Plenum, New York (Cancer: a comprehensive treatise, vol 5, p 309)Google Scholar
  131. LePage GA (1978 a) Resistance to 9-β-D-arabinofuranosyladenine in murine tumor cells. Cancer Res 38:2314–2316PubMedGoogle Scholar
  132. LePage GA (1978 b) some model systems in cancer chemotherapy. In: Scholefield PG (ed) Proceedings of the 10th Canadian Cancer Conference. University of Toronto Press, Toronto, p 171Google Scholar
  133. LePage GA, Gottlieb J A (1973) Deoxythioguanosine and thioguanine. Clin Pharmacol Ther 14:966–969PubMedGoogle Scholar
  134. LePage GA, Hersh EM (1972) Cyclic nucleotide analogs as carcinostatic agents. Biochem Biophys Res Commun 46:1918–1922PubMedGoogle Scholar
  135. LePage GA, Jones M (1961a) Purinethiols as feedback inhibitors of purine synthesis in ascites tumor cells. Cancer Res 21:642–649PubMedGoogle Scholar
  136. LePage GA, Jones M (1961b) Further studies on the mechanism of action of 6-thioguanine. Cancer Res 21:1590–1594PubMedGoogle Scholar
  137. LePage GA, Junga IG (1963) Use of nucleosides in resistance to 6-thioguanine. Cancer Res 23:739–743PubMedGoogle Scholar
  138. LePage GA, Junga IG (1967) The utilization of a-2’-deoxythioguanosine by murine tumor cells. Mol Pharmacol 3:37–43PubMedGoogle Scholar
  139. LePage GA, Khaliq A (1979) Responses of patients to arabinosyladenine-5′-phosphate correlated with an in vitro test. In: Weber G (ed) Advances in enzyme regulation, vol. 17. Pergamon, Oxford p 437Google Scholar
  140. LePage GA, Naik S (1975) Biochemical pharmacology of a new thiopurine nucleoside derivative. Ann NY Acad Sci 255:481PubMedGoogle Scholar
  141. LePage GA, White SC (1973) Scheduling of arabinosylcytosine and 6-thioguanine therapy. Cancer Res 33:946–949PubMedGoogle Scholar
  142. LePage GA, Junga IG, Bowman B (1964) Biochemical and carcinostatic effects of 2’-deoxythioguanosine. Cancer Res 24:835–840PubMedGoogle Scholar
  143. LePage GA, Lin YT, Orth RE; Gottlieb JA (1972) 5′-Nucleotides as potential formulations for administering nucleoside analogs in man. Cancer Res 32:2441–2444PubMedGoogle Scholar
  144. LePage GA, Naik SR, Kattakar SB, Khaliq A (1975) 9-£-D-Arabinofuranosyladenine-5′-phosphate metabolism and excretion in humans. Cancer Res 35:3036–3040PubMedGoogle Scholar
  145. LePage GA, Worth LS, Kimball AP (1976) Enhancement of the antitumor activity of arabinofuranosyladenine by 2,-deoxycoformycin. Cancer Res 36:1481–1485PubMedGoogle Scholar
  146. Lesch M, Nyhan WL (1964) A familial disorder of uric acid metabolism and central nervous system function. Am J Med 36:561–574PubMedGoogle Scholar
  147. Li CL, Lee MH, Sartorelli AC (1979) Synthesis and biological evaluation of tetramisole analogues as inhibitors of alkaline phosphatase of the 6-thiopurine-resistant tumor Sarcoma 180/TG. J Med Chem 22:1030–1033PubMedGoogle Scholar
  148. Littlefield JW (1963) The inosinic acid pyrophosphorylase activity of mouse fibroblasts partially resistant to 8-azaguanine. Proc Natl Acad Sci USA 50:568–576PubMedGoogle Scholar
  149. Lomax CA, Henderson JF (1972) Phosphorylation of adenosine and deoxyadenosine in Ehrlich ascites carcinoma cells resistant to 6-(methylmercapto)purine ribonucleoside. Can J Biochem 50:423–427PubMedGoogle Scholar
  150. Mandel HG (1959) The physiological disposition of some anticancer agents. Pharmacol Rev 11:743–838PubMedGoogle Scholar
  151. Marchesi SL, Sartorelli AC (1963) The biochemical basis for the differential sensitivity of intestinal mucosa and bone marrow to 6-thioguanine. Cancer Res 23:1769–1773PubMedGoogle Scholar
  152. Martin WR, Crichton IK, Yang RC, Evans AE (1972) The metabolism of thioinosinic acid by 6-mercaptopurine sensitive and resistant leukemic leukocytes. Proc Soc Exp Biol Med 140:423–428PubMedGoogle Scholar
  153. McDonald J A, Kelley WN (1971) Lesch-Nyhan syndrome: altered kinetic properties of mutant enzyme. Science 171:689–691PubMedGoogle Scholar
  154. Meyer RB Jr, Stone TE, Ullman B (1979) 2’-0-Acyl-6-thioinosine cyclic 3,5 -phosphates as prodrugs of thioinosinic acid. J Med Chem 22:811–815PubMedGoogle Scholar
  155. Meyers MB, Shin S (1981) Specific resistance to 8-azaguanine in cells with normal hypoxanthine phosphoribosyltransferase (HPRT) activity: the role of guanine deaminase. Cytogenet Cell Genet 30:118–128PubMedGoogle Scholar
  156. Meyers MB, Van Diggelen OP, Van Diggelen M, Shin S (1980) Isolation of somatic cell mutants with specified alterations in hypoxanthine phosphoribosyltransferase. Somatic Cell Genet 6:299–306PubMedGoogle Scholar
  157. Montgomery JA (1974) Rational design of purine nucleoside analogs. In: Sartorelli AC, Johns DG (eds) Antineoplastic and immunosuppressive agents. Springer, Berlin Heidelberg New York (Handbook of experimental pharmacology, vol 38/1, p 76)Google Scholar
  158. Montgomery JA, Thomas HJ, Schaeffer HJ (1961) Synthesis of potential anticancer agents. XXVIII. Simple esters of 6-mercaptopurine ribonucleotide. J Org Chem 25:1929–1933Google Scholar
  159. Montgomery JA, Dixon GJ, Dulmage EA, Thomas HJ, Brockman RW, Skipper HE (1963) Inhibition of 6-mereaptopurine-resistant cancer cells in culture by bis-(thioinosine)-5′,5″-phosphate. Nature 199:769–772Google Scholar
  160. Moore EC, LePage GA (1958) The metabolism of 6-thioguanine in normal and neoplastic tissues. Cancer Res 18:1075–1083PubMedGoogle Scholar
  161. Morrow J (1970) Genetic analysis of azaguanine resistance in an established mouse cell line. Genetics 65:279–287PubMedGoogle Scholar
  162. Nakai Y, LePage GA (1972) Characterization of the kinase(s) involved in the phosphorylation of α- and β-2’deoxythioguanosine. Cancer Res 32:2445–2451PubMedGoogle Scholar
  163. Nelson J A, Parks RE Jr (1972) Biochemical mechanism for the synergism between 6-thio-guanine and 6-(methylmercapto)purine ribonucleoside in sarcoma 180 cells. Cancer Res 32:2034–2041PubMedGoogle Scholar
  164. Nelson J A, Carpenter JW, Rose LM, Adamson DJ (1975 a) Mechanism of action of 6-thioguanine, 6-mercaptopurine, and 8-azaguanine. Cancer Res 35:2872–2878Google Scholar
  165. Nelson JA, Kuhns JN, Carpenter JW (1975 b) Lack of activity of β-2’-deoxythioguanosine against two tumors resistant to 6-thioguanine. Cancer Res 35:1372–1374PubMedGoogle Scholar
  166. Nichol CA (1975) Antibiotics resembling adenosine: tubercidin, toyocamycin, sangivamycin, formycin, psicofuranine and decoyinine. In: Sartorelli AC, Johns DG (eds) Antineoplastic and immunosuppressive agents. Springer, Berlin Heidelberg New York (Handbook of experimental pharmacology, vol 38/2, p 434)Google Scholar
  167. Omura GA (1975) Phase II trial of beta-deoxythioguanosine (β-TGdR, NSC 71261) in refractory adult acute leukemia. Proc Am Assoc Cancer Res 16:140Google Scholar
  168. Parks RE Jr, Agarwal KC (1975) 8-Azaguanine. In: Sartorelli AC, Johns DG (eds) Antineoplastic and immunosuppressive agents. Springer, Berlin Heidelberg New York (Handbook of experimental pharmacology, vol 38/2, p 458)Google Scholar
  169. Parks RE Jr, Crabtree GW, Kong CM, Agarwal RP, Agarwal KC, Scholar EM (1975) Incorporation of analog purine nucleosides into the formed elements of human blood: erythrocytes, platelets and lymphocytes. Ann NY Acad Sci 255:412PubMedGoogle Scholar
  170. Paterson ARP (1959) The formation of 6-mercaptopurine riboside phosphate in acites tumor cells. Can J Biochem Physiol 37:1011–1023PubMedGoogle Scholar
  171. Paterson ARP (1960) The development of resistance to 6-mercaptopurine in a subline of the Ehrlich ascites carcinoma. Can J Biochem Physiol 38:1117–1127PubMedGoogle Scholar
  172. Paterson ARP (1962) Resistance to 6-mercaptopurine. II. The synthesis of thioinosinate in a 6-mercaptopurine-resistant subline of the Ehrlich ascites carcinoma. Can J Biochem Physiol 40:195–206PubMedGoogle Scholar
  173. Paterson ARP, Hori A (1962) Resistance to 6-mercaptopurine. I. Biochemical differences between the Ehrlich ascites carcinoma and a 6-mercaptopurine-resistant subline. Can J Biochem Physiol 40:181–194PubMedGoogle Scholar
  174. Paterson ARP, Moriwaki A (1969) Combination chemotherapy: synergistic inhibition of lymphoma L5178Y cells in culture and in vivo with 6-mercaptopurine and 6-(methylmercapto)purine ribonucleoside Cancer Res 29:681–686PubMedGoogle Scholar
  175. Paterson ARP, Sutherland A (1964) Metabolism of 6-mercaptopurine ribonucleoside by Ehrlich ascites carcinoma cells. Can J. Biochem 42:1415–1423PubMedGoogle Scholar
  176. Paterson ARP, Tidd DM (1975) 6-Thiopurines. In: Sartorelli AC, Johns DG (eds) Antineoplastic and immunosuppressive agents. Springer, Berlin Heidelberg New York (Handbook of experimental pharmacology, vol 38/2, p 384)Google Scholar
  177. Paterson ARP, Wang MC (1970) Mechanism of the growth inhibition potentiation arising from combination of 6-mercaptopurine with 6-(methylmercapto)purine ribonucleoside. Cancer Res 30:2379–2386PubMedGoogle Scholar
  178. Peery A, LePage GA (1969) Nucleotide formation from a- and β-2’-deoxythioguanosine in extracts of murine and human tissues. Cancer Res 29:617–623PubMedGoogle Scholar
  179. Pierre KJ, LePage GA (1968) Formation of inosine-5′-monophosphate by a kinase in cell-free extracts of Ehrlich ascites cells in vitro. Proc Soc Exp Biol Med 127:432–440PubMedGoogle Scholar
  180. Pierre KJ, Kimball AP, LePage GA (1967) The effect of structure on nucleoside kinase activity. Can J Biochem 45:1619–1632PubMedGoogle Scholar
  181. Plunkett W, Cohen SS (1975) Two approaches that increase the activity of analogs of adenine nucleosides in animal cells. Cancer Res 35:1547–1554PubMedGoogle Scholar
  182. Plunkett W, Cohen SS (1977) Penetration of mouse fibroblasts by 2’-deoxyadenosine 5′-phosphate and incorporation of the nucleotide into DNA. J Cell Physiol 91:261–270PubMedGoogle Scholar
  183. Plunkett W, Alexander L, Chubb S, Loo TL (1979) Biochemical basis of the increased activity of 9-β-D-arabinofuranosyladenine in the presence of inhibitors of adenosine deaminase. Cancer Res 39:3655–3660PubMedGoogle Scholar
  184. Plunkett W, Chubb S, Alexander L, Montgomery J A (1980) Comparison of the toxicity and metabolism of 9-β-D-arabinofuranosyl-2-fluoroadenine and 9-β-D-arabinofuranosyladenine in human lymphoblastoid cells. Cancer Res 40:2349–2355PubMedGoogle Scholar
  185. Plunkett W, Benjamin R, Feun L, Keating M, Freireich EJ (1981) Cellular concentrations of dATP and araATP in peripheral blood leukemic cells and erythrocytes from patients treated with deoxycoformycin and arabinosyladenine. Proc Am Assoc Cancer Res 22:177Google Scholar
  186. Rivest RS, Irwin D, Mandel HG (1982) Purine analogs revisited: interference in protein formation. Adv Enzyme Regul 20:351–373PubMedGoogle Scholar
  187. Rose LM, Brockman RW (1977) Analysis by high pressure liquid chromatography of 9-β-D-arabinofuranosyladenine 5-triphosphate (AraATP) levels in murine leukaemia cells. J Chromatogr 133:335–343PubMedGoogle Scholar
  188. Rosman M, Williams HE (1973) Leukocyte purine phosphoribosyltransferases in human leukemias sensitive and resistant to 6-thiopurines. Cancer Res 33:1202–1209PubMedGoogle Scholar
  189. Rosman M, Lee MH, Creasey WA, Sartorelli AC (1974) Mechanisms of resistance to 6-thiopurines in human leukemia. Cancer Res 34:1952–1956PubMedGoogle Scholar
  190. Ross AF, Agarwal KC, Chu S-H, Parks RE Jr (1973) Studies on the biochemical actions of 6-selenoguanine and 6-selenoguanosine. Biochem Pharmacol 22:141–154PubMedGoogle Scholar
  191. Roy-Burman P (1970) Analogues of nucleic acid components. Springer, Berlin Heidelberg New York (Recent results in cancer research, vol 25)Google Scholar
  192. Rubin CS, Dancis J, Yip LC, Nowinski RC, Balis ME (1971) Purification of IMP: pyrophosphate phosphoribosyltransferases, catalytically incompetent enzymes in Lesch-Nyhan disease. Proc Natl Acad Sci USA 68:1461–1464PubMedGoogle Scholar
  193. Sartorelli AC, LePage GA (1957) Modification of thioguanine toxicity in tumor-bearing mice with bone marrow transplants. Proc Am Assoc Cancer Res 2:246Google Scholar
  194. Sartorelli AC, LePage GA, Moore EC (1958) Metabolic effects of 6-thioguanine. I. Studies on thioguanine-resistant and -sensitive Ehrlich ascites cells. Cancer Res 18:1232–1239PubMedGoogle Scholar
  195. Sartorelli AC, Lee MH, Rosman M, Agrawal KC (1975) Mechanisms of resistance to 6-thiopurines by neoplastic cells. In: Pharmacological basis of cancer chemotherapy. Williams & Wilkins, Baltimore, P 643Google Scholar
  196. Scannell JP, Hitchings GH (1966) Thioguanine in deoxyribonucleic acid from tumors of 6-mercaptopurine-treated mice. Proc Soc Exp Biol Med 122:627–629PubMedGoogle Scholar
  197. Schabel FM Jr (1975) Synergism and antagonism among antitumor agents. In: Pharmacological basis of cancer chemotherapy. Williams & Wilkins, Baltimore, p 595Google Scholar
  198. Schabel FM Jr, Trader MW, Laster WR Jr (1976) Increased therapeutic activity of 9-β-D-arabinofuranosyladenine against leukemia P388 and L1210 by an adenosine deaminase inhibitor. Proc Am Assoc Cancer Res 17:46Google Scholar
  199. Schacter B, Law LW (1957) Azaguanine-deaminase activity of several lymphocytic leukemias of mice. J Natl Cancer Inst 18:77–81Google Scholar
  200. Schmid FA, Hutchison DJ, Otter GM, Stock CC (1976) Development of resistance to combinations of six antimetabolites in mice with L1210 leukemia. Cancer Treat Rep 60:23–27PubMedGoogle Scholar
  201. Schmidt LH, Montgomery J A, Laster WR Jr, Schabel FM Jr (1970) Combination therapy with arabinosylcytosine and thioguanine. Proc Am Assoc Cancer Res 11:70Google Scholar
  202. Schnebli HP, Hill DL, Bennett LL Jr (1967) Purification and properties of adenosine kinase from human tumor cells of type H.Ep.No.2. J Biol Chem 242:1997–2004PubMedGoogle Scholar
  203. Scholar EM, Calabresi P (1973) Identification of the enzymatic pathways of nucleotide metabolism in human lymphocytes and leukemia cells. Cancer Res 33:94–103PubMedGoogle Scholar
  204. Scholar EM, Calabresi P (1979) Increased activity of alkaline phosphatase in leukemic cells from patients resistant to thiopurines. Biochem Pharmacol 28:445–446PubMedGoogle Scholar
  205. Scholar EM, Brown PR, Parks RE Jr (1972) Synergistic effect of 6-mercaptopurine and 6-methylmercaptopurine ribonucleoside on the levels of adenine nucleotides of sarcoma 180 cells. Cancer Res 32:259–269PubMedGoogle Scholar
  206. Scott JL (1962) Human leukocyte metabolism in vitro. I. Incorporation of adenine-8-C14 and formate-C14 into the nucleic acids of leukemic leukocytes. J Clin Invest 41. 67–79PubMedGoogle Scholar
  207. Scott JL, Marino JV, Gabor EP (1966) Human leukocyte metabolism in vitro. II. The effect of 6-mercaptopurine on formate-C14 incorporation into the nucleic acids of acute leukemic leukocytes. Blood 28:683–691PubMedGoogle Scholar
  208. Seegmiller JE, Rosenbloom FM, Kelley WN (1967) Enzyme defect associated with a sex-linked human neurological disorder and excessive purine synthesis. Science 155:1682–1684PubMedGoogle Scholar
  209. Sekiguchi T, Sekiguchi F, Tomii S (1974) Complementation in hybrid cells derived from mutagen-induced mouse clones deficient in hypoxanthine-guanine phosphoribosyl-transferase activity. Exp Cell Res 88:410–414PubMedGoogle Scholar
  210. Sekiguchi T, Sekiguchi F, Tomii S (1975) Genetic complementation in hybrid cells derived from mutagen-induced mouse clones deficient in HGPRT activity. Exp Cell Res 93:207–218PubMedGoogle Scholar
  211. Sharp JD, Capecchi NE, Capecchi MR (1973) Altered enzymes in drug-resistant variants of mammalian tissue culture cells. Proc Natl Acad Sci USA 70:3145–3149PubMedGoogle Scholar
  212. Shigiura HT, Boxer GE, Sampson SD, Meloni ML (1965) Metabolism of 2-fluoro-adenosine by Ehrlich ascites cells. Arch Biochem Biophys 111:713–719Google Scholar
  213. Shin S-I (1974) Nature of mutations conferring resistance to 8-azaguanine in mouse cell lines. J Cell Sci 14:235–251PubMedGoogle Scholar
  214. Skaper SD, Spector EB, Seegmiller JE (1977) Reversion in expression of hypoxanthine-guanine phosphoribosyltransferase in 6-thioguanine resistant neuroblastoma: evidence for reduced enzyme levels associated with unaltered catalytic activity. J Cell Physiol 92:275–284PubMedGoogle Scholar
  215. Skipper HE (1975) Closing remarks. In: Pharmacological basis of cancer chemotherapy. Williams & Wilkins, Baltimore, p 713Google Scholar
  216. Skipper HE, Montgomery J A, Thomson JR, Schabel FM Jr (1959) Structure-activity relationships and cross-resistance observed on evaluation of a series of purine analogs against experimental neoplasms. Cancer Res 19:425–437PubMedGoogle Scholar
  217. Smellie RMS, Thomson RY, Davidson JN (1958) The nucleic acid metabolism of animal cells in vitro. I. The incorporation of 14C-formate. Biochim Biophys Acta 29:59–74PubMedGoogle Scholar
  218. Smith JL, Omura GA, Krakoff IH, Balis ME (1971) IMP: and AMP: pyrophosphate phosphoribosyltransferase in leukemic and normal human leukocytes. Proc Soc Exp Biol Med 136:1299–1303PubMedGoogle Scholar
  219. Stutts P, Brockman RW (1963) A biochemical basis for resistance of L1210 mouse leukemia to 6-thioguanine. Biochem Pharmacol 12:97–104PubMedGoogle Scholar
  220. Suttle DP, Harkrader RJ, Jackson RC (1981) Pyrazofurin-resistant hepatoma cells deficient in adenosine kinase. Eur J Cancer 17:43–51PubMedGoogle Scholar
  221. Tamaoki T, LePage GA (1975) Inhibition of DNA chain growth by a-2’-deoxythio-guanosine. Cancer Res 35:1103–1105PubMedGoogle Scholar
  222. Terzi M (1974) Chromosomal variation and the origin of drug-resistant mutants in mammalian cell lines. Proc Natl Acad Sci USA 71:5027–5031PubMedGoogle Scholar
  223. Thomas HJ, Montgomery J A (1968) Deriatives and analogs of 6-mercaptopurine ribonucleotide. J Med Chem 11:44–48PubMedGoogle Scholar
  224. Thompson LF, Willis RC, Stoop JW, Seegmiller JE (1978) Purine metabolism in cultured human fibroblasts derived from patients deficient in hypoxanthine phosphoribosyltransferase, purine nucleoside phosphorylase, or adenosine deaminase. Proc Natl Acad Sci USA 75:3722–3726PubMedGoogle Scholar
  225. Tidd DM, Dedhar S (1978) Specific and sensitive combined high-performance liquid chromatographic-flow fluorometric assay for intracellular 6-thioguanine nucleotide metabolites of 6-mercaptopurine and 6-thioguanine. J Chromatogr 145:237–246PubMedGoogle Scholar
  226. Tidd DM, Paterson ARP (1974 a) Distinction between inhibition of purine nucleotide synthesis and the delayed cytotoxic reaction of 6-mercaptopurine. Cancer Res 34:733–737Google Scholar
  227. Tidd DM, Paterson ARP (1974 b) A biochemical mechanism for the delayed cytotoxic reaction of 6-mercaptopurine. Cancer Res 34:738–746PubMedGoogle Scholar
  228. Tidd DM, Gibson I, Dean PDG (1981) Acylated dinucleoside phosphate derivatives as agents to overcome resistance to purine antimetabolites. Br J Cancer 43:733Google Scholar
  229. Tidd DM, Johnston HP, Gibson I (1982 a) Effects of bis(6-mercaptopurine-9-β-D-ribofuranoside)-5′, 5”‘-phosphate and its butyryl derivative on mouse leukaemia LI210 and a 6-mercaptopurine-resistant subline in culture. Biochem Pharmacol 31:2903–2912Google Scholar
  230. Tidd DM, Gibson I, Dean PDG (1982 b) Partial circumvention of resistance to 6-mercaptopurine by acylated P1, P2-bis(6-mercaptopurine-9-β-D-ribofuranoside-5′) pyrophosphate derivatives. Cancer Res 42:3769–3775PubMedGoogle Scholar
  231. Tsou KC, Ledis S, Bennett LL (1975) Synthesis of 5-iodo-3-indolyl phosphodiester of 6-methylthiopurine ribonucleoside (MeMPR) and its activity in an MeMPR-resistant tissue culture line. In: Pharmacological basis of cancer chemotherapy. Williams & Wilkins, Baltimore, p 239Google Scholar
  232. Van Diggelen OP, Donahue TF, Shin S-I (1979) Basis for differential cellular sensitivity to 8-azaguanine and 6-thioguanine. J Cell Physiol 98:59–72PubMedGoogle Scholar
  233. Van Zeeland A A, De Ruijter YCEM, Simons JWIM (1974) The role of 8-azaguanine in the selection from human diploid cells of mutants deficient in hypoxanthine-guanine-phosphoribosyl-transferase (HGPRT). Mutat Res 23:55–68Google Scholar
  234. Wagar MA, Taber RL, Huberman J A (1979) Studies on the penetration of mammalian cells by deoxyribonucleoside-5′-phosphates. J Cell Physiol 101:251–259Google Scholar
  235. Wolpert MK, Damle SP, Brown JE, Sznycer E, Agarwal KC, Sartorelli AC (1971) The role of phosphohydrolases in the mechanism of resistance of neoplastic cells to 6-thio-purines. Cancer Res 31:1620–1626PubMedGoogle Scholar
  236. Wotring LL, Roti Roti JL (1980) Thioguanine-induced S and G2 blocks and their significance to the mechanism of cytotoxicity. Cancer Res 40:1458–1462PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1984

Authors and Affiliations

  • D. M. Tidd

There are no affiliations available

Personalised recommendations